Skin Infection Clinical Trial
Official title:
A Pilot Randomized Controlled Trial Assessing the Effectiveness of Alcohol Swabs in Preventing Infections in Pediatric Patients Receiving Vaccinations
Alcohol is used to disinfect the skin prior to injections in order to prevent infections caused by bacteria on the skin being injected within tissue. At present, however, clinical trials do not demonstrate a clinical impact of using or not using alcohol swabs on infections and infection symptoms calling into question the practice of using it prior to all injections. These studies are methodologically flawed, and do not specifically examine vaccine injections. The present study is being undertaken to provide some preliminary data for the risk of infection and infection symptoms when alcohol swabs are not used to perform vaccine injections.
Alcohol is used to disinfect the skin prior to injections in order to prevent infections
caused by bacteria on the skin being injected within tissue. Alcohol has been shown to be a
good disinfectant, reducing the number of bacteria on skin by 47-91%. However, in previous
clinical trials, there has been no clinical impact of using or not using alcohol swabs on
infections and infection symptoms calling into question the practice of using it prior to
all injections. These studies, however, are generally of low scientific rigor (e.g., not
randomized, not blinded, did not use standard case definitions of the adverse reactions
being measured). Moreover, it is important to note that none of them specifically evaluated
vaccine injections, the most common type of injection worldwide.
At present, based on the available evidence base, the World Health Organization (WHO) and
the Centre for Disease Control (CDC) do not recommend the use of alcohol swabs before
vaccine injections. As a result, immunizers in many countries around the world currently do
not cleanse the skin with alcohol prior to vaccination. Despite these recommendations,
clinicians in our community and across Canada commonly use alcohol swabs prior to all
vaccine injections. In this application, investigators will undertake a pilot randomized
study to evaluate the incidence of infection symptoms and infections in children undergoing
vaccination with and without skin cleansing with alcohol swabs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
| Completed |
NCT03929224 -
The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown
|
Phase 4 | |
| Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Recruiting |
NCT03637400 -
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
|
Phase 2 | |
| Completed |
NCT06149117 -
Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China
|
Phase 4 | |
| Active, not recruiting |
NCT05226260 -
Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
|
N/A | |
| Recruiting |
NCT04278404 -
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
|
||
| Terminated |
NCT03372941 -
Hospital Avoidance Strategies for ABSSSI
|
Phase 4 | |
| Completed |
NCT02512614 -
Evaluation of Novel Antimicrobial Hand Towels
|
Phase 2/Phase 3 | |
| Completed |
NCT01593761 -
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
|
Phase 2 | |
| Not yet recruiting |
NCT06247761 -
STASSH - TRAUMA - Absorbable vs Non-Absorbable Sutures in Trauma Hand Surgery
|
N/A | |
| Not yet recruiting |
NCT06170983 -
Skin Inflammation and PK of Azithromycin
|
N/A | |
| Completed |
NCT02052388 -
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
|
Phase 2 | |
| Completed |
NCT00619710 -
Complicated Skin and Skin Structure Infections
|
Phase 3 | |
| Recruiting |
NCT05339802 -
A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections
|
Phase 2 | |
| Completed |
NCT06087809 -
Improving Short Course Treatment for Common Pediatric Infections
|
N/A | |
| Not yet recruiting |
NCT05899140 -
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
|
Phase 4 |